OcuNexus Therapeutics Appoints Dr. Brian Levy as Chief Executive Officer San Diego, California – January 2nd, 2017 – OcuNexus Therapeutics, Inc. announced today that it has named Brian Levy, O.D., M.Sc as Chief Executive. The appointment of Dr. Levy is key to the continuing development of novel targeted therapies that address major unmet medical needs in ophthalmology.  “OcuNexus has worked with Dr. Levy in a consulting capacity over the last year, and we are excited that he has agreed to join the Company as its Chief Executive Officer,” said Chairman Jim Mervis.  “We believe that Dr. Levy’s experience and capabilities will be key to our ongoing success and we are delighted to have him lead our management team.” Recently OcuNexus had a successful Type C meeting with the FDA that established the path to NDA enabling commencement of Phase 3 studies with its lead product Nexagon® in non-healing Corneal Persistent Epithelial Defects (PED). “OcuNexus has highly differentiated, lead drug candidates are based upon a novel mechanism of action called “Gap Junction Channel Modulation” that specifically targets a protein called Connexin43 and the inflammasome mediated pathway of inflammation” commented Dr. Levy. “OcuNexus is developing unique, patented therapeutics to treat ophthalmic diseases with high unmet needs that offer the potential to alter the standard of care.” Dr Levy has spent his career in ophthalmology and is a proven leader with a depth of experience in Drug and Device Development, Clinical Development and Medical Affairs. Dr. Levy has led 3 NDA's in Ophthalmic Pharmaceuticals, all approved and commercialized; Multiple PMA's and 510K’s for Cataract, Refractive and Vitreo-Retinal Surgical Devices, Intra Ocular Lenses and Contact Lenses in the US and Internationally including Europe and Asia. Dr. Levy was most recently Chief Medical Officer at Aerie Pharmaceuticals where he was a member of the Executive team that took the company public through a successful IPO. Prior to that he spent 15 years at Bausch & Lomb as Vice President R&D and then Chief Medical Officer for the Corporation. In these evolutionary roles he was responsible for Global Clinical and Product Development, Global Product Safety and Medical Affairs. ### For further information please contact: Dr Brian Levy, CEO, OcuNexus Therapeutics, Inc. Phone: +1 585-978-1943 E-mail: brian@ocunexus.com David Pool, CFO, OcuNexus Therapeutics, Inc. Phone: +1 858-405-9271 E-mail: david@ocunexus.com              

OcuNexus Therapeutics Appoints Dr. Brian Levy as Chief Executive Officer

San Diego, California – January 2nd, 2017 – OcuNexus Therapeutics, Inc. announced today that it has named Brian Levy, O.D., M.Sc as Chief Executive. The appointment of Dr. Levy is key to the continuing development of novel targeted therapies that address major unmet medical needs in ophthalmology. 

“OcuNexus has worked with Dr. Levy in a consulting capacity over the last year, and we are excited that he has agreed to join the Company as its Chief Executive Officer,” said Chairman Jim Mervis.  “We believe that Dr. Levy’s experience and capabilities will be key to our ongoing success and we are delighted to have him lead our management team.”

Recently OcuNexus had a successful Type C meeting with the FDA that established the path to NDA enabling commencement of Phase 3 studies with its lead product Nexagon® in non-healing Corneal Persistent Epithelial Defects (PED).

“OcuNexus has highly differentiated, lead drug candidates are based upon a novel mechanism of action called “Gap Junction Channel Modulation” that specifically targets a protein called Connexin43 and the inflammasome mediated pathway of inflammation” commented Dr. Levy. “OcuNexus is developing unique, patented therapeutics to treat ophthalmic diseases with high unmet needs that offer the potential to alter the standard of care.”

Dr Levy has spent his career in ophthalmology and is a proven leader with a depth of experience in Drug and Device Development, Clinical Development and Medical Affairs. Dr. Levy has led 3 NDA's in Ophthalmic Pharmaceuticals, all approved and commercialized; Multiple PMA's and 510K’s for Cataract, Refractive and Vitreo-Retinal Surgical Devices, Intra Ocular Lenses and Contact Lenses in the US and Internationally including Europe and Asia. Dr. Levy was most recently Chief Medical Officer at Aerie Pharmaceuticals where he was a member of the Executive team that took the company public through a successful IPO. Prior to that he spent 15 years at Bausch & Lomb as Vice President R&D and then Chief Medical Officer for the Corporation. In these evolutionary roles he was responsible for Global Clinical and Product Development, Global Product Safety and Medical Affairs.

###

For further information please contact:

Dr Brian Levy, CEO, OcuNexus Therapeutics, Inc.
Phone: +1 585-978-1943
E-mail: brian@ocunexus.com

David Pool, CFO, OcuNexus Therapeutics, Inc.
Phone: +1 858-405-9271
E-mail: david@ocunexus.com